Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer

Annals of Surgical Oncology

Volumn 11, Issue 6, 2004, Pages 612-618

  Tanaka, Fumihiro ^a   Yanagihara, Kazuhiro ^a   Otake, Yosuke ^b   Kawano, Yozo ^a   Miyahara, Ryo ^a   Takenaka, Kazumasa ^a   Katakura, Hiromichi ^a   Ishikawa, Shinya ^a   Ito, Harumi ^c   Wada, Hiromi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Seishin Iryo Center Hospital   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

Angiogenesis; N2; Non small cell lung cancer; Proliferative activity; Stage IIIA; Surgery

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PREOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; ARTICLE; JAPAN; LUNG RESECTION; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 4043170480     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.07.013     Document Type: Review

References (25)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;116:1710-7.
2. Tanaka F, Yanagihara K, Otake Y, et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. Eur J Cardiothonic Surg 2000;18:147-55.
3. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997;63:1441-50.
4. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the significant node that affects survival? J Thorac Curdiovasc Surg 1999;118:270-5.
5. Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001;34:29-36.
6. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
7. Angeletti CA, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2) Cancer 1996;78:409-15.
8. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alternations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
9. Tanaka F, Otake Y, Yanagihara K, et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001;84:263-9.
10. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-5.
11. American Society of Clinical Oncology. ASCO special article: Clinical practical guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996-3018.
12. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.
13. Tanaka F, Yanagihara K, Otake Y, et al. Biological features and preoperative evaluation of mediastinal nodal status in non-small cell lung cancer. Ann Thorac Surg 2000;70:1832-8.
14. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classification of Tumors: Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin: Springer, 1999.
15. Wada H, Hitomi S, Teramatsu T, West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996;14:1048-54.
16. Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in resected stage I-II NSCLC (non-small-cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999;15:438-43.
17. Tanaka F, Kawano Y, Li M, et al. Prognostic significance of apoptotic index in completely resected non-small cell lung cancer. J Clin Oncol 1999;17:2728-36.
18. Folkman J, Watson K, Ingiber D, Hanahan D. Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature (Lond) 1989;339:58-61.
19. Harpole Jr DH, Richards WG, Herndon II JE, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470-6.
20. Lucchi M, Fontanini G, Mussi A, et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 1997;12:535-41.
21. Duarte IG, Bufkin BL, Pennington MF, et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Caridovasc Surg 1998;115:652-9.
22. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997;15:2456-66.
23. Tanaka F, Yanagohara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 2001;19:555-61.
24. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-9.
25. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2000;19:111-8.